INS and metabolic syndrome: With the MIN6 insulinoma cell line, treatment has been demonstrated by a FA mixture that mimics the analytical composition of the metabolic syndrome; elevated LCFAs reduced insulin secretory function after 27 h, decreased viability, and reduced also mitochondrial energy metabolism and induced fission.